Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)

Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)

Resection of colorectal liver metastases (CRLM) is a potential curative treatment for patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD). Although long-term survival improved considerably within the last decades, high recurrence rates of 50-75% after resection remain...

Full description

Bibliographic Details
Main Authors: Carl Christoph Schimanski, Stefan Kasper, Susanna Hegewisch-Becker, Jan Schröder, Friedrich Overkamp, Frank Kullmann, Wolf Otto Bechstein, Matthias Vöhringer, Robert Öllinger, Florian Lordick, Volker Heinemann, Michael Geißler, Armin Schulz-Abelius, Helga Bernhard, Michael R. Schön, Richard Greil, Peter Galle, Hauke Lang, Irene Schmidtmann, Markus Moehler
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
tecemotide (l-blp25)
mucin-1 (muc1)
colorectal neoplasms
liver-limited disease
resection of colorectal liver metastases
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1806680

Internet

http://dx.doi.org/10.1080/2162402X.2020.1806680

Similar Items